Dr. Masood is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
535 Barnhill Dr
Indianapolis, IN 46202Phone+1 317-944-0920Fax+1 816-932-5793
Summary
- I am Director of Gastrointestinal Medical Oncology and Co-Director, Rush Precision Oncology Program at Rush University Medical Cancer. I am board certified in medical oncology, hematology, and internal medicine.
Previously, I was an Assistant Professor in the Division of Oncology at Washington University School of Medicine in Saint Louis and UMKC -KC/ Saint Luke's Cancer Institute, specializing is gastrointestinal cancers.
I am trained in bioinformatics and computational biology . I have carried out Next Gen Sequencing analysis including Whole genome ,whole exome , RNA seq Analysis, proteomic analysis independently . Furthermore , I program using python, perl , R programming languages.
My current research focus is to develop effective biomarker-driven therapies to our cancer patients. Furthermore, my other focus to study large genomic datasets to discover novel and clinically actionable alterations to help to develop newer effective treatments in our patients.
During my clinical fellowship, I was a post-doctoral fellow in Scott Devine's Lab at the Institute for Genomic Sciences at the University of Maryland. I was involved in research in Devine’s lab, which led to the discovery that transposons (jumping genes) can initiate colorectal cancer.
Education & Training
- University of MarylandFellowship, Hematology and Medical Oncology, 2012 - 2015
- Wayne State University School of MedicineResidency, Internal Medicine, 2009 - 2012
- OtherClass of 2007, MBBS
Certifications & Licensure
- IN State Medical License 2021 - 2025
- IL State Medical License 2018 - 2023
- KS State Medical License 2016 - 2019
- MO State Medical License 2015 - 2019
- MI State Medical License 2009 - 2013
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of SEA-CD40 in Cancer Patients Start of enrollment: 2015 Feb 28
- Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Start of enrollment: 2015 Apr 30
- BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer Start of enrollment: 2016 Jun 06
Publications & Presentations
PubMed
- Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity.Ateeq M Khaliq, Meenakshi Rajamohan, Omer Saeed, Kimia Mansouri, Asif Adil
Nature Genetics. 2024-11-01 - 1 citationsSingle-Cell Profiling Reveals the Impact of Genetic Alterations on the Differentiation of Inflammation-Induced Murine Colon Tumors.Ahmed H Ghobashi, Rosie Lanzloth, Christopher A Ladaika, Ashiq Masood, Heather M O'Hagan
Cancers. 2024-05-28 - 9 citationsHigh-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival.Erik P Storrs, Prathamesh Chati, Abul Usmani, Ian Sloan, Bradley A Krasnick
NPJ Precision Oncology. 2023-10-19
Press Mentions
- Pancreatic Cancer Tumor Map Uncovers Notable Differences Between Primary and Metastatic DiseaseOctober 4th, 2024
- Why Is Colon Cancer Rising Among Young Adults?March 29th, 2023
- Rush Named National Center of Excellence for Pancreatic CancerFebruary 14th, 2020
Professional Memberships
- Member
Other Languages
- Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: